Friday, September 29, 2017 4:42:54 PM
GW Pharma slips 15% premarket on Zogenix's successful late-stage study of ZX008 in Dravet
Sep. 29, 2017 7:48 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor
GW Pharmaceuticals (NASDAQ:GWPH) is down 15% premarket, albeit on only 779 shares, in apparent response to Zogenix's announcement of positive Phase 3 results for Dravet syndrome candidate ZX008.
GW's late-stage candidate for Dravet is Epidiolex (cannabidiol).
Previously: Zogenix's lead candidate ZX008 successful in late-stage Dravet study (Sept. 29)
Previously: GW Pharma initiates second Phase 3 study of Epidiolex in Dravet syndrome (April 21, 2015)
https://seekingalpha.com/news/3298365-gw-pharma-slips-15-percent-premarket-zogenixs-successful-late-stage-study-zx008-dravet
I dislike linking Seeking Alpha articles but this one seems to be dead on.
Know What You Own. My posts should not be construed as investment advice.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM